These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 17580855)
21. HPFP, a model propellant for pMDIs. Rogueda PG Drug Dev Ind Pharm; 2003 Jan; 29(1):39-49. PubMed ID: 12602491 [TBL] [Abstract][Full Text] [Related]
22. Reverse aqueous microemulsions in hydrofluoroalkane propellants and their aerosol characteristics. Selvam P; Bharatwaj B; Porcar L; da Rocha SR Int J Pharm; 2012 Jan; 422(1-2):428-35. PubMed ID: 22044539 [TBL] [Abstract][Full Text] [Related]
23. Predicting physical stability in pressurized metered dose inhalers via dwell and instantaneous force colloidal probe microscopy. D'Sa D; Chan HK; Chrzanowski W Eur J Pharm Biopharm; 2014 Sep; 88(1):129-35. PubMed ID: 25058596 [TBL] [Abstract][Full Text] [Related]
24. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002 [TBL] [Abstract][Full Text] [Related]
25. The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers. Liao YH; Brown MB; Jones SA; Nazir T; Martin GP Int J Pharm; 2005 Nov; 304(1-2):29-39. PubMed ID: 16181753 [TBL] [Abstract][Full Text] [Related]
26. A Review of Methods for Evaluating Particle Stability in Suspension Based Pressurized Metered Dose Inhalers. D'Sa D; Chan HK Curr Pharm Des; 2015; 21(27):3955-65. PubMed ID: 26290200 [TBL] [Abstract][Full Text] [Related]
27. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients. Dusser D; Vicaut E; Lefrançois G; Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009 [TBL] [Abstract][Full Text] [Related]
28. Reformulation of Stmerin(®) D CFC formulation using HFA propellants. Murata S; Izumi T; Ito H Pharm Dev Technol; 2013; 18(6):1314-8. PubMed ID: 22519407 [TBL] [Abstract][Full Text] [Related]
29. Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy. Hoe S; Young PM; Rogueda P; Traini D AAPS PharmSciTech; 2008; 9(2):605-11. PubMed ID: 18459053 [TBL] [Abstract][Full Text] [Related]
30. Insulin nanoparticles: stability and aerosolization from pressurized metered dose inhalers. Nyambura BK; Kellaway IW; Taylor KM Int J Pharm; 2009 Jun; 375(1-2):114-22. PubMed ID: 19481697 [TBL] [Abstract][Full Text] [Related]
31. Novel pMDI formulations for pulmonary delivery of proteins. Li HY; Seville PC Int J Pharm; 2010 Jan; 385(1-2):73-8. PubMed ID: 19854252 [TBL] [Abstract][Full Text] [Related]
32. Understanding solvation in the low global warming hydrofluoroolefin HFO-1234ze propellant. Yang L; da Rocha SR J Phys Chem B; 2014 Sep; 118(36):10675-87. PubMed ID: 25137437 [TBL] [Abstract][Full Text] [Related]
33. The effect of reduction of propellant mass fraction on the injection profile of metered dose inhalers. Ju D; Shrimpton J; Hearn A Int J Pharm; 2010 May; 391(1-2):221-9. PubMed ID: 20227471 [TBL] [Abstract][Full Text] [Related]
34. Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: a colloidal probe microscopy investigation. Wu L; da Rocha SR Langmuir; 2007 Nov; 23(24):12104-10. PubMed ID: 17958454 [TBL] [Abstract][Full Text] [Related]
35. The CFC to HFA transition and its impact on pulmonary drug development. Leach CL Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403 [TBL] [Abstract][Full Text] [Related]